WO2006092106A3 - Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. - Google Patents

Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. Download PDF

Info

Publication number
WO2006092106A3
WO2006092106A3 PCT/CU2006/000001 CU2006000001W WO2006092106A3 WO 2006092106 A3 WO2006092106 A3 WO 2006092106A3 CU 2006000001 W CU2006000001 W CU 2006000001W WO 2006092106 A3 WO2006092106 A3 WO 2006092106A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
central nervous
neurogeneration
ghrp
egf
Prior art date
Application number
PCT/CU2006/000001
Other languages
English (en)
French (fr)
Other versions
WO2006092106A2 (es
Inventor
Del Barco Herrera Diana Garcia
Nieto Gerardo Enrique Guillen
Acosta Jorge Amador Berlanga
Almeida Freya De Los Mi Freyre
Vera Danay Cibrian
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Del Barco Herrera Diana Garcia
Nieto Gerardo Enrique Guillen
Acosta Jorge Amador Berlanga
Almeida Freya De Los Mi Freyre
Vera Danay Cibrian
Arias Eduardo Penton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Del Barco Herrera Diana Garcia, Nieto Gerardo Enrique Guillen, Acosta Jorge Amador Berlanga, Almeida Freya De Los Mi Freyre, Vera Danay Cibrian, Arias Eduardo Penton filed Critical Ct Ingenieria Genetica Biotech
Priority to AU2006220154A priority Critical patent/AU2006220154B2/en
Priority to DE602006006903T priority patent/DE602006006903D1/de
Priority to AT06705745T priority patent/ATE431743T1/de
Priority to US11/885,330 priority patent/US20100093616A1/en
Priority to EP06705745A priority patent/EP1870106B1/en
Priority to JP2007557312A priority patent/JP5001180B2/ja
Priority to MX2007010717A priority patent/MX2007010717A/es
Priority to CA2600628A priority patent/CA2600628C/en
Priority to CN2006800139592A priority patent/CN101180044B/zh
Priority to BRPI0607844A priority patent/BRPI0607844B8/pt
Priority to KR1020077022024A priority patent/KR101255200B1/ko
Publication of WO2006092106A2 publication Critical patent/WO2006092106A2/es
Publication of WO2006092106A3 publication Critical patent/WO2006092106A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención es dirigida a estimular la neuroregeneración del sistema nervioso central debido al daño autoinmune. En particular la combinación farmacéutica que comprende concentraciones terapéuticamente efectivas del Factor de Crecimiento Epidérmico y del Hexapéptido Secretagogo de la Hormona de Crecimiento Humana es administrada a un sujeto que sufre de los síntomas de Esclerosis Múltiple y Neuromielitis Óptica y corrige la desmielinización causada por células autoreactivas en el Sistema Nervioso Central.
PCT/CU2006/000001 2005-03-02 2006-02-24 Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. WO2006092106A2 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2006220154A AU2006220154B2 (en) 2005-03-02 2006-02-24 Combination of EGF/GHRP-6 for neurogeneration of central nervous system
DE602006006903T DE602006006903D1 (de) 2005-03-02 2006-02-24 Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems
AT06705745T ATE431743T1 (de) 2005-03-02 2006-02-24 Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems
US11/885,330 US20100093616A1 (en) 2005-03-02 2006-02-24 Combination of EGF/GHRP-6 for Neurogeneration of Central Nervous System Following Autoimmune Damage
EP06705745A EP1870106B1 (en) 2005-03-02 2006-02-24 Combination of egf/ghrp-6 for neuroregeneration of central nervous system
JP2007557312A JP5001180B2 (ja) 2005-03-02 2006-02-24 自己免疫障害後の中枢神経系の神経再生に用いるｅｇｆ／ｇｈｒｐ−６の組合せ
MX2007010717A MX2007010717A (es) 2005-03-02 2006-02-24 Combinacion de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al dano autoinmune.
CA2600628A CA2600628C (en) 2005-03-02 2006-02-24 Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage
CN2006800139592A CN101180044B (zh) 2005-03-02 2006-02-24 用于自身免疫损伤后中枢神经系统神经再生的egf/ghrp-6组合
BRPI0607844A BRPI0607844B8 (pt) 2005-03-02 2006-02-24 uso do egf e ghrp-6
KR1020077022024A KR101255200B1 (ko) 2005-03-02 2006-02-24 자가면역 손상에 따른 중추 신경계의 신경 재생용ｅｇｆ/ｇｈｒｐ-6의 조합

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20050043A CU23529A1 (es) 2005-03-02 2005-03-02 Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune
CU2005-0043 2005-03-02

Publications (2)

Publication Number Publication Date
WO2006092106A2 WO2006092106A2 (es) 2006-09-08
WO2006092106A3 true WO2006092106A3 (es) 2006-12-14

Family

ID=40280698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2006/000001 WO2006092106A2 (es) 2005-03-02 2006-02-24 Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune.

Country Status (18)

Country Link
US (1) US20100093616A1 (es)
EP (1) EP1870106B1 (es)
JP (1) JP5001180B2 (es)
KR (1) KR101255200B1 (es)
CN (1) CN101180044B (es)
AT (1) ATE431743T1 (es)
AU (1) AU2006220154B2 (es)
BR (1) BRPI0607844B8 (es)
CA (1) CA2600628C (es)
CU (1) CU23529A1 (es)
DE (1) DE602006006903D1 (es)
ES (1) ES2327562T3 (es)
MX (1) MX2007010717A (es)
MY (1) MY142494A (es)
PT (1) PT1870106E (es)
RU (1) RU2403913C2 (es)
WO (1) WO2006092106A2 (es)
ZA (1) ZA200707020B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
CU24591B1 (es) 2018-08-21 2022-04-07 Ct Ingenieria Genetica Biotecnologia Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento
ES2967696T3 (es) 2019-04-08 2024-05-03 Giuseppe Scalabrino Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030675A2 (en) * 1998-11-25 2000-06-02 A+ Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
EP1506997A1 (en) * 2003-08-14 2005-02-16 NeuroProgen GmbH Leipzig Method of generating neural stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030675A2 (en) * 1998-11-25 2000-06-02 A+ Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARSENIJEVIC Y AND WEISS S: "Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neural precursors: Distinct actions from those of brain-derived neurotrophic factor", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 6, 15 March 1998 (1998-03-15), pages 2118 - 2128, XP002146610, ISSN: 0270-6474 *
FRAGO LAURA M ET AL: "Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection", ENDOCRINOLOGY, vol. 143, no. 10, October 2002 (2002-10-01), pages 4113 - 4122, XP002395581, ISSN: 0013-7227 *
HARVEY STEVE ET AL: "Neural growth hormone: an update.", JOURNAL OF MOLECULAR NEUROSCIENCE : MN. FEB 2003, vol. 20, no. 1, February 2003 (2003-02-01), pages 1 - 14, XP009071227, ISSN: 0895-8696 *
KNAPP PAMELA E ET AL: "Epidermal growth factor promotes oligodendrocyte process formation and regrowth after injury.", EXPERIMENTAL CELL RESEARCH. 10 JUN 2004, vol. 296, no. 2, 10 June 2004 (2004-06-10), pages 135 - 144, XP002395583, ISSN: 0014-4827 *
KUHN H G ET AL: "Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 17, no. 15, 1997, pages 5820 - 5829, XP002229396, ISSN: 0270-6474 *
PLATA-SALAMAN C R: "EPIDERMAL GROWTH FACTOR AND THE NERVOUS SYSTEM", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 12, no. 3, May 1991 (1991-05-01), pages 653 - 663, XP001181067, ISSN: 0196-9781 *
RAINETEAU OLIVIER ET AL: "Neurogenesis in hippocampal slice cultures", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 26, no. 2, June 2004 (2004-06-01), pages 241 - 250, XP002395584, ISSN: 1044-7431 *
ROM POULSEN F ET AL: "Glutamate receptor antagonists and growth factors modulate dentate granule cell neurogenesis in organotypic, rat hippocampal slice cultures", BRAIN RESEARCH, AMSTERDAM, NL, vol. 1051, no. 1-2, 27 July 2005 (2005-07-27), pages 35 - 49, XP004984668, ISSN: 0006-8993 *
SCHNEIDER HARALD JOERN ET AL: "Central effects of the somatotropic system.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 149, no. 5, November 2003 (2003-11-01), pages 377 - 392, XP002395582, ISSN: 0804-4643 *

Also Published As

Publication number Publication date
JP2008531607A (ja) 2008-08-14
ES2327562T3 (es) 2009-10-30
ATE431743T1 (de) 2009-06-15
CU23529A1 (es) 2010-06-17
DE602006006903D1 (de) 2009-07-02
AU2006220154A1 (en) 2006-09-08
CA2600628C (en) 2013-04-09
KR20070107790A (ko) 2007-11-07
RU2007136280A (ru) 2009-04-10
BRPI0607844B1 (pt) 2018-08-28
RU2403913C2 (ru) 2010-11-20
EP1870106B1 (en) 2009-05-20
ZA200707020B (en) 2009-08-26
CN101180044B (zh) 2010-12-08
BRPI0607844A2 (pt) 2010-10-19
AU2006220154B2 (en) 2010-05-27
CA2600628A1 (en) 2006-09-08
US20100093616A1 (en) 2010-04-15
MY142494A (en) 2010-11-30
CN101180044A (zh) 2008-05-14
WO2006092106A2 (es) 2006-09-08
EP1870106A2 (en) 2007-12-26
JP5001180B2 (ja) 2012-08-15
MX2007010717A (es) 2007-10-12
KR101255200B1 (ko) 2013-04-23
PT1870106E (pt) 2009-08-25
BRPI0607844B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
WO2011154126A3 (en) Skin antiaging treatment
EP2455462A3 (en) Lipase variants for pharmaceutical use
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
WO2009117041A3 (en) Use of pyrene to carry peptides across the blood brain barrier
EP1623046A4 (en) COMPOSITIONS AND METHODS FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
WO2006031398A3 (en) Compositions containing fast-leaching plasticizers for improved performance of medical devices
EP2628749A3 (en) Antimicrobial kinocidin compostions and methods of use
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
WO2006032923A3 (en) Inhibitors of protein kinase a anchoring
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
WO2005121328A3 (en) Method for ameliorating an inflammatory skin condition
WO2006113647A3 (en) Recovery of tissue function following administration of b cells to injured tissue
WO2008063865A3 (en) Biphosphonate inhalant formulations and methods for using the same
WO2006092106A3 (es) Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune.
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2005102374A3 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2010057275A8 (en) Cyclic peptides and uses thereof
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2000058466A3 (en) Protease resistant flint analogs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010717

Country of ref document: MX

Ref document number: 2007557312

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2600628

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020077022024

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006705745

Country of ref document: EP

Ref document number: 7537/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006220154

Country of ref document: AU

Ref document number: 2007136280

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006220154

Country of ref document: AU

Date of ref document: 20060224

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200680013959.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006220154

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006705745

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11885330

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0607844

Country of ref document: BR

Kind code of ref document: A2